Achievements

30,000 compounds screened in P. vivax liver-stage assays

84% of patients recruited in CANTAM study

MMV's Key Achievements graphic

128 million vials of Artesun® delivered to treat children with severe malaria

385 million treatments of Coartem® Dispersible delivered to over 50 countries

First single-dose medicine to prevent the relapse of P. vivax approved by US FDA

Two rectal artesunate suppository products for pre-referral management of severe malaria approved

81 million courses of seasonal malaria chemoprevention delivered to countries in the Sahel in 2018

Pyramax® Granules added to the WHO's Model List of Essential Medicines for Children

10 compounds in clinical development

150 active partners in MMV's network, working to help defeat malaria

319 Pathogen Boxes shipped

>90% of severe malaria cases now treated with injectable artesunate in preference to quinine

18,000 health-care workers trained to administer injectable artesunate for severe malaria

USD 1 = USD 3.5 of investment impact thanks to direct and in-kind support from partners

>25 drug targets validated since 1999

MMV wins Open Data Innovation Award for work on the Malaria Box
Dr David Reddy, CEO, MMV and Dr Bernard Pécoul, CEO, DNDi

2 ACTs developed by DNDi and partners transitioned to MMV

More than 200,000 doses of Eurartesim® distributed in two ground-breaking mass drug administration pilots

Key landmarks for MMV-supported medicines